clinical trial · NCT06742190
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
argenx·phase3·recruiting·n = 115
Multifocal Motor Neuropathy (MMN)MMNEmpasiprubartIVIG (Intravenous Immunoglobulin)Empasiprubart-placeboIVIg-placebo
brief summary
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found here: https://clinicaltrials.argenx.com/empassion
started
Dec 18, 2024
primary completion
Sep 1, 2026
completion
Dec 1, 2029
last updated
Mar 13, 2026
official title
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol